Want to join the conversation?
$AMGN said its Phase 3 GAUSS-3 trial evaluating drug Repatha (evolocumab) in patients with high cholesterol, who cannot tolerate statins, met its co-primary endpoints. GAUSS-3 is a three-part trial that is evaluating the safety, tolerability and efficacy of Repatha.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.